Phase I trial of KN046, a novel bispecific antibody targeting PD-L1 and CTLA-4 in patients with advanced solid tumors

BACKGROUND: KN046 is a novel bispecific antibody targeting programmed death ligand 1 (PD-L1) and cytotoxic T lymphocyte-associated protein 4 (CTLA-4). This multicenter phase I trial investigated the safety, tolerability, pharmacokinetics (PK), and efficacy of KN046 in patients with advanced solid tu...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Yuxiang, Xue, Jinhui, Zhao, Yuanyuan, Zhang, Yang, Huang, Yan, Yang, Yunpeng, Fang, Wenfeng, Guo, Ye, Li, Qun, Ge, Xiaoxiao, Sun, Jie, Zhang, Bangyong, Zhang, Yuhan, Xiao, Jinyuan, Zhang, Li, Zhao, Hongyun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10254625/
https://www.ncbi.nlm.nih.gov/pubmed/37263673
http://dx.doi.org/10.1136/jitc-2022-006654

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10254625/
https://www.ncbi.nlm.nih.gov/pubmed/37263673
http://dx.doi.org/10.1136/jitc-2022-006654

Ejemplares similares